FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.2  |  FHIR Version n/a  User: [n/a]

61360007: Polymyxin B sulfate (substance)


Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2002. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
101950019 Polymyxin B sulfate en Synonym (core metadata concept) Active Only initial character case insensitive (core metadata concept) SNOMED CT core
498992017 Polymyxin B sulphate en Synonym (core metadata concept) Active Only initial character case insensitive (core metadata concept) SNOMED CT core
800413012 Polymyxin B sulfate (substance) en Fully specified name Active Only initial character case insensitive (core metadata concept) SNOMED CT core
2727021000005113 Polymyxin B-sulfat da Synonym (core metadata concept) Active Only initial character case insensitive (core metadata concept) Danish module (core metadata concept)


0 descendants.

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
Polymyxin B sulfate Is a Product containing polymyxin B (medicinal product) false Inferred relationship Some
Polymyxin B sulfate Is a Polymyxin B (substance) false Inferred relationship Some
Polymyxin B sulfate Is a Polymyxin (substance) true Inferred relationship Some
Polymyxin B sulfate Is a Drug allergen false Inferred relationship Some
Polymyxin B sulfate This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. Polymyxin B (substance) true Inferred relationship Some
Polymyxin B sulfate This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Antibacterial (disposition) true Inferred relationship Some

Inbound Relationships Type Active Source Characteristic Refinability Group
Polymyxin B sulf [systemic] The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
Polymyxin B sulf [eye] The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
Polymyxin B sulfate [skin] The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
polymyxin B-sulfat 100 % pulver The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
polymyxin B-sulfat + trimethoprim øjendråber The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
polymyxin B-sulfat + bacitracinzink øjensalve The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
polymyxin B-sulfat + trimethoprim øjensalve The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
polymyxin B-sulfat + bacitracinzink 10.000 enheder/500 enheder øjensalve The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
Bacitracin zinc + neomycin sulfate + polymyxin b sulfate 400unt/5mg/10000unt ointment The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
bacitracinzink 500 enheder + polymyxin B-sulfat 10.000 enheder salve The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/5 mg/1,6 mg suspension The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/5 mg/10.000 opløsning The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
hydrocortison 10 mg + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/7,5 mg/10.000 enheder suspension The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
hydrocortison 10 mg + neomycinsulfat 7,5 mg + polymyxin B-sulfat 1.000 enheder opløsning The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
hydrocortisonacetat 5 mg + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder creme The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
neomycinsulfat + polymyxin B-sulfat + prednisolonacetat 0,35 %/10.000 enheder/0,5 % wt/vol suspension The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
polymyxin B-sulfat + trimethoprimsulfat 10.000 enheder/1 mg opløsning til oftalmisk anvendelse The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
neomycinsulfat + polymyxin B-sulfat + prednisolonacetat The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
gramicidin + neomycinsulfat + polymyxin B-sulfat The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
Polymyxin b sulfate + trimethoprim sulfate The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
bacitracinzink + neomycinsulfat + polymyxin B-sulfat The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
hydrocortison + neomycinsulfat + polymyxin B-sulfat The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
dexamethason + neomycinsulfat + polymyxin B-sulfat The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
Bacitracin zinc + polymyxin b sulfate The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
Polymyxin B sulfate 500,000u powder for injection solution vial The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
Product containing hydrocortisone and neomycin sulfate and polymyxin B sulfate and zinc bacitracin The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Polymyxin B sulfate Inferred relationship Some
Polymyxin B (as polymyxin B sulfate) 500000 unit powder for solution for injection vial The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Polymyxin B sulfate Inferred relationship Some 1

This concept is not in any reference sets

Back to Start